Management of Upper Extremity Deep Vein Thrombosis

Assessment and Management Approach

The American College of Cardiology recommends continuing current anticoagulation therapy with appropriate dose adjustment and monitoring for patients with upper extremity deep vein thrombosis (UEDVT) who are already on oral anticoagulants 1
Determine if the current anticoagulation is therapeutic by checking appropriate laboratory parameters, such as INR for warfarin, or clinical assessment for DOACs, to assess therapeutic status 1
Assess for potential causes of anticoagulation failure, including inadequate dosing or poor medication adherence 2
Drug-drug interactions affecting anticoagulant metabolism should be considered as a potential cause of anticoagulation failure 3
Cancer-associated thrombosis may require more intensive therapy 4

For cancer patients with UEDVT already on anticoagulants, the National Comprehensive Cancer Network recommends considering switching to LMWH or DOACs if on warfarin, and continuing current therapy unless contraindicated by gastrointestinal or genitourinary malignancies 2, 4
Extended duration of therapy is recommended while cancer is active or under treatment 4
For catheter-associated UEDVT in patients already on anticoagulants, evaluate necessity of the catheter and remove if no longer needed, and continue anticoagulation for at least 3 months or as long as catheter remains in place 2, 4

If the patient develops bleeding while on anticoagulation, assess severity of bleeding using standardized criteria and consider continuing anticoagulation with local measures to control bleeding for non-major bleeding without hemodynamic compromise 7, 8
For major bleeding, temporarily discontinue anticoagulation and consider reversal agents based on the specific anticoagulant, such as Vitamin K with or without prothrombin complex concentrate for warfarin, Idarucizumab for dabigatran, and Andexanet alfa for apixaban or rivaroxaban 7, 9

Continue therapy for at least 3 months for provoked UEDVT, at least 6-12 months for unprovoked UEDVT, and indefinite anticoagulation for recurrent thrombosis or persistent risk factors 5, 10
Indefinite anticoagulation is recommended for active cancer 2, 4

Regular clinical assessment for symptoms of post-thrombotic syndrome and recurrent thrombosis is recommended, along with periodic reassessment of bleeding risk versus thrombotic risk 7
Consider compression sleeves for symptomatic relief and prevention of post-thrombotic syndrome 10